Among th e adve rse d erm atologi c manifest ations associa te d wit h d ru g t he ra py, Ste ve ns -j o h ns on Synd ro me (SjS) st ands ou t as a se ve re, pot ent iall y lethal adve rse e ffec t. SjS has be en a ssociated with th e us e of ca r ba maze pine a nd a lso phen ob a rb ita l and phen ytoin, most ly in neurological cases. It is of int e r est to not e th at in th e case of ca r ba m a ze pine, th e first su ch d es cribed case occurred in th e year it wa s int roduced (I) . The overall in cid en ce from studies of ca r ba maze pine -ind uced SjS is low (an av erage of about 5 per 1,000,000 ca se s) and is co ns ide re d un comm on (2 ,3,4) . C arbamazepine is an iminodibenzyl d erivative with a structure sim ilar to th e t ricyclic antid epressants. In clin ica l neurology , ca rba maze pine has been effec t ive in th e tre atm ent of psychomotor and grand m a l se izu re s, as well as trigeminal ne u ralgia.
SjS is a clinical syndrom e presum ed to be a hyp ersen sitivity rea cti on m a nifest ed initia lly with prodrom a l symptoms offever, malaise and a sore throat. T he p ro d rom al phase is then fo llow ed in som e days (up to 14 days) by an ac u te poly m or ph ous d ermatologic synd ro me manifest ed as e ryt he mat ous m acul o-papular lik e lesions, target lesions, bullae, vesicles, invo lvem ent of a t lea st two mu cou s m em b ra nes, conj u nc tivitis and an associated syst emic toxic stat e.
Sin ce the japanese (5) postulat ed and d escribed th e pos sibl e effec t ive ne ss of ca r ba m a ze pine in affective disorders and the subsequ ent con fir mat ion of thi s in lat e r controlled clinica l trials (6), ca rbam a ze pine has been in cr easingly used by psychi a- trist s as a mood st abilizer. Alon g with th e incre asing use of carbamazepin e in co n te m por ary psychi at ric practice is the rare occ urre nce of SJS as a sid e e ffec t. H owever, very few cases hav e been d escribed in t he psychi a t ric lit e ra t u re so far (7) . W e present a case of ca rbamaze pine-associa te d SJS in a psyc hiat r ic pati ent wh o a lso had d iabet es m ellitus a nd was a lso o n treatm ent with g lybu r ide in our institution .
CASE REPORT
A th irty-five year o ld ca ucasia n mal e , single, domiciled , u nemployed , coll eg e ed uca te d wit h a g rea ter tha n 15 years psychi atric hist ory a nd multiple past psychi atric ad m iss ions, treated in th e past wit h hal op eridol a nd lithium wa s ad m itted to our institution on Febru ary 6, 1994, with a lon g di a gn osis of sc hizoaffect ive d isorde r. On ad m ission , a long with paranoid a nd g ra nd iose d elusion s, the patient a lso had a pronounced m anic state . H e was start ed on hal op eridol, lithium a nd ben ztropine. Since he al so su ffere d fro m ad ult onset diabet es mell itu s (d iagnosed in a not he r in stitution a yea r ag o pri o r to this a dm iss ion) , an d was on trea t m en t with regular insulin as a n ou t pa tie n t, thi s was co n t in ue d .
On a d m ission, t he pat ient had fluctuating mildly incr ea sed blood suga r levels, for whi ch th e unit int ernist pr escribed g lyb u rid e wh ile th e patient was weaned off insul in . G lyburide was sta rte d e igh t d ays after ad m iss ion . Fro m the pa st hi st ory th e pat ient was not co m plia n t with lithiu m thera py an d th is was a lso confi rmed up on admission when he refused to tak e lithi um . H e su bseq ue nt ly rep ort ed t hat he was non -co mplian t on lithiu m because of a fixed idea th at his sis ter was co lla borati ng wit h hi s th e ra pist to la bel him a bipolar in order to disqualify him from a fa mi ly inhe rit ance.
As the pat ien t's man ic syndrome continued, an a lternative mood st abilizer was so ug h t. Carbamazepine was found acceptable to t he patient as a substitut e for lithiu m ten days after admission. Carbamazepine was begun and t itra ted u pwa rd s. T en days a fte r initiation of ca r ba m a ze pine the ra py, t he patient d eveloped flu-like symptoms with a sore throat. Two days lat e r, he d eveloped d ermato log ic lesions consisti ng p rin cipally of an e ryt he m a to us maculpapula r rash. G lybu ri de wa s d iscont inued as this react ion was th o ught to have been ca used by th e m ed ica tion . A slid ing sca le regular insu lin coverage regimen was ins titut ed in place of g lybu rid e, wh ile th e pat ie n t re m a in ed o n hal op erid ol a nd ca rbamazepine. In addition , ora l pr ed nisone 40 m g wa s add ed to t he t rea tme n t.
Th ree d ays a fter the a ppearance of th e flu-like symptoms and d e rmatologic ra sh , th e d erma tol ogy co ns ultan t d ia gn osed drug-induced morbillifor m e ru p t io n secondary to g lyburide. The d ermat o logist reco m m e nde d cont in ued t rea t me nt with oral pr ednisone, whil e add ing tr iamcin olon e for d e rmal a pplicat ion. H oweve r, t he pat ien t's d erm al eru p t ion got wo rse, a nd he d evel op ed bleeding in tranasal lesion s, ulcera ti ng bu ccal lesion s, incr eas ed m al ai se, a nd ge neralize d bodil y aches a nd di scomfort. H e m at ological a nd blood che m istry work up results were within normal limit s. T wo d ays from t he firs t d ermatologic cons u lt, a sus picion of possibl e SJS was rai sed a nd a second d erm a tology consu lt was sought. At thi s ti me, th e pa t ie n t was feb ril e ( 100 F) a nd beca use of th e oral lesion s had d ifficult y ea t ing. Revi ew of th e case by th e se nior d erma tologi st led to diagnosis of SJS attrib ut ed to ca rba m a ze pine . (T wo days before the ini tial d ermal e ru p tion, t he serum ca r ba m a ze pine leve l was 8.4 f.l.g/ml ; two days after the eruption se rum carbarnazepine level m easured 9.3 f.l.g /m l) . Carbama zepine was dis co ntinued im m edia tely and because of the worse n ing physica l cond it ion of the patient , a d ecision was made to transfer t he patient to the medica l floor.
T rea t m e n t o n th e m edical floor consisted of ha loperidol, oral pr ednisone a nd a sliding scale insulin coverage regim en. Seven days from th e beginnin g of the flu-like symptom s, the int ermittent nasal bleedin g subsided, the feelin g of malaise was reduced, and oral lesions sta rted showing signs of remis sion. Th e pati ent 's manic symptoms, along wit h the delusions , had now almost resolved . Pati ent was discharged home from the medicine unit thirty-two days afte r his initi al psychiatric admission with plans for follow up in the outpa tient psychiatry and medicine clinics. A suggestion was also mad e for a trial with valproic acid as a mood stabi lizer.
DISCUSSION AND COMMENTARY
A sm a ll number of psychotropics have been associat ed with SJS, fr equ e n tly cited are ph enobarbital, ph enytoin, fluoxitin e , meprobamat e a nd ca rba mazepine (8, 9) . In the psychiatry literature , ca r ba m a ze pine-a ssoc ia te d SJS has been rare . The first such d escribed ca se was report ed in the United States ( 10) th e mo st recent cas e wa s r eport ed from Canada (II) .
Considering the pot entially lethal consequ en ces of SJS a nd th e in cr easin g use of ca r ba m a ze pine in psychiatry (not only as a mood st abilizer, but a lso for oth er psychiatric indications including impulse control and alc oh ol d etoxificati on ) (12) , co n t in ue d us e of ca r ba m a ze pine sho uld be considered agains t the ba ck grou nd o f cu r re n t th erapeutic information. Som e authors have s ug ges te d a n increased r isk of SJS wh en neuroleptics are co m bine d with ca rba maze pine (13) . Others have recomm end ed pat ch testing prospective recipi ents for hyp ersensitivit y to t he d rug (14) . Thi s sho uld, however, be done havin g in mind the risk of a fal se posi tive t est result a nd a n occa sional unpl eas ant d erm at ologic reaction to th e pa tch ( 15) . Other authors hav e postulat ed a po ssibl e d esensitization procedu r e for ca rba maze pine hype rs ensitivity reaction s ( 16) . The id ea o f d esen sitizin g ca rba maze pine-ind uce d SJS pati ent s see ms plausible , but co ns ide r ing th e so me t imes fulminan t a nd let ha l course of thi s synd ro me , the ou tcome in th ese pa ti ent s m ight ca r ry a far bigger ris k. Consid ering th e relative benefit a nd ex panded use o f ca rbamazepine in psyc h ia try, psychiatrist s nee d to assess the clinica l use of this dru g on a case by case basis wi t h an awa re ness of th e associa te d adve rse r ea ction s.
This particul ar case wa s uniqu e co nsi de ri ng th e fac t th at t he pa tie nt was al so a di abetic on glybu r ide. Initi all y, a t th e m anifest ation s of th e prodromal signs thi s posed a probl em of di agnosis, co ns ide r ing that glybu r ide is a su lfo nylurea com pou nd . Althou gh so me cases ofSJS have been associa te d with use of so m e s ulp hur-containing drugs ( 17, 18) , a thorough searc h fail ed to d emonstrat e a case or cita tion for SJS induced by glyb u r ide .
In thi s case, eve n a fte r the g lyb u r ide was di scont inu ed and th e pa tient was ma in taine d o n ca rba maze pine, pr ednison e a nd hal op e r idol , t he cli nica l picture worsen ed until the carba maze pine was di scontin ued . This makes a plaus ible case for consid e ring carbamaze pine as th e SJS inducer. Thi s cas e , to da te , is th e second psyc h ia t r ic ca se of ca r ba m a ze pine-ind uced SJS in a pat ient in th e Un ited Stat es since t he orig inal wa s publish ed in 1987 (7) .
Fin all y, to r educe th e in cid ence of ca rbamazepine-induced SJS In psychi atric practice , we sugges t a risk assessme n t profile approach (as used In preventive m edicine practice ) wh en ca r ba maze pine th erapy is be in g consid e re d. Thi s e n ta ils co ns ide ra t ion of and application of a ll inform at ion as pe rt ains to ca rba maze pine hyp ersen sitivity, po ssible ass oc ia t ion of th e synd rom e in neurolep t ic carbam azep ine co m bina t ions , cons ide rat ion for usin g ot he r kn own a lte rnat ive to carbam azepine with sim ila r d esired e ffec ts (fo r exam ple, valproic ac id). In th e e nd, when a d ecisio n is m ad e to proceed with ca r ba maze pine therapy, a m ore proactive approach o f inquirin g fro m patient s about sym ptoms /sig ns associa t ed wit h the prodrom al stage o f t he synd ro me shou ld be so ug h t. In th e sa me light , th e pati ent sho uld be instruct ed a nd t au ght to look ou t for sym p to ms a nd sig ns a nd im me dia te ly in for m th e sta ff to faci lita te ea r ly int ervention a nd secondary prevention of this syndrom e .
